XBiotech Inc (XBIT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the XBIT SEC filings page.
This page shows XBiotech Inc (XBIT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
XBiotech operates like a development-stage business: rising R&D and cash losses are shrinking a still-liquid, lightly indebted balance sheet.
From FY2024 to FY2025, the net loss widened from$38.5M to$45.5M while operating cash outflow moved from$31.0M to$39.9M ; that close alignment suggests reported losses are translating largely into cash use rather than being driven mainly by noncash charges.
R&D reached
Assets contracted to
Financial Health Signals
XBiotech Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
XBiotech Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.
XBiotech Inc reported a net loss of $45.5M while operations used $39.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
XBiotech Inc reported an operating loss of $55.7M against $88K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
XBiotech Inc's EBITDA was -$5.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 0.9% from the same quarter a year earlier. Against the prior quarter it is up 1.6%.
XBiotech Inc reported -$6.7M in net income in Q2 2026. This represents a decrease of 283.1% from the same quarter a year earlier. Against the prior quarter it is down 22.2%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
XBiotech Inc recorded an outflow of $4.5M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 25.2% from the same quarter a year earlier. Against the prior quarter it is up 49.7%.
XBiotech Inc held $109.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
XBiotech Inc's ROE was -5.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 4.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.2 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
XBiotech Inc invested $5.3M in research and development in Q2 2026. This represents a decrease of 0.7% from the same quarter a year earlier. Against the prior quarter it is up 1.7%.
XBiotech Inc reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Not reported for Q2 2026.
XBIT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $5.3M-0.7% | $5.2M-55.2% | N/A | $5.1M-28.7% | $5.3M-58.9% | $11.6M+18.3% | N/A | $7.1M-5.6% |
| SG&A Expenses | $850K-15.0% | $1.1M-44.7% | N/A | $967K+24.5% | $1.0M-49.5% | $1.9M+87.8% | N/A | $777K-20.1% |
| Operating Income | -$6.1M+3.0% | -$6.3M+53.7% | N/A | -$6.0M+23.5% | -$6.3M+57.7% | -$13.6M-24.9% | N/A | -$7.9M+7.2% |
| EBITDA | -$5.8M+0.9% | -$5.9M+54.7% | N/A | -$5.6M+24.7% | -$5.9M+59.4% | -$13.1M-25.8% | N/A | -$7.5M+7.7% |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $88K-56.0% | N/A | $203K |
| Income Tax | $46K+64.3% | $49K+69.0% | N/A | $102K+1033.3% | $28K+212.0% | $29K+16.0% | N/A | $9K-97.1% |
| Net Income | -$6.7M-283.1% | -$5.5M+49.4% | N/A | -$6.0M-19.8% | -$1.8M+86.5% | -$10.9M-8.8% | N/A | -$5.0M+31.9% |
| EPS (Basic) | -$0.22-266.7% | -$0.18+50.0% | -$0.88-158.8% | -$0.20-25.0% | -$0.06+86.0% | -$0.36-9.1% | -$0.34-126.7% | -$0.16+33.3% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EPS (Diluted), Diluted Shares (Avg).
XBIT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $133.7M-25.2% | $139.8M-23.1% | $150.1M-24.6% | $172.4M-17.8% | $178.7M-17.1% | $181.9M-20.2% | $199.1M-12.1% | $209.9M-8.6% |
| Current Assets | $111.2M-28.2% | $117.0M-25.8% | $127.0M-27.3% | $149.0M-19.5% | $154.9M-18.8% | $157.7M-22.3% | $174.6M-13.5% | $185.0M-9.5% |
| Cash & Equivalents | $109.5M-28.4% | $115.5M-25.9% | $125.6M-27.3% | $147.4M-19.5% | $152.9M-18.9% | $155.9M-22.5% | $172.7M-13.7% | $183.1M-9.4% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | N/A | N/A | N/A | $450K-38.4% | $480K-44.8% | $480K-44.8% | $700K-18.6% | $730K-17.1% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $5.2M-7.6% | $4.8M-32.6% | $9.7M-42.2% | $5.3M-69.9% | $5.6M-70.2% | $7.2M-61.5% | $16.8M+116.6% | $17.7M+155.6% |
| Current Liabilities | $3.4M-13.1% | $3.0M-44.6% | $7.9M-47.5% | $3.6M-77.7% | $3.9M-77.5% | $5.4M-68.0% | $15.1M+147.6% | $16.0M+202.1% |
| Non-Current Liabilities | $1.8M+4.3% | $1.8M+4.5% | $1.8M+4.8% | $1.8M+2.0% | $1.8M+2.4% | $1.7M+2.8% | $1.7M+3.1% | $1.7M+6.0% |
| Total Equity | $128.5M-25.8% | $135.0M-22.7% | $140.3M-23.0% | $167.1M-13.0% | $173.1M-12.0% | $174.7M-16.5% | $182.3M-16.7% | $192.1M-13.7% |
| Retained Earnings | -$148.6M-43.6% | -$141.9M-39.5% | -$136.4M-50.1% | -$109.5M-36.3% | -$103.5M-37.4% | -$101.7M-63.3% | -$90.8M-73.7% | -$80.3M-68.5% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
XBIT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.5M+24.6% | -$9.0M-33.5% | -$23.0M-250.9% | -$4.3M+27.1% | -$6.0M+47.4% | -$6.7M+6.7% | -$6.5M-90.5% | -$5.8M-293.1% |
| Depreciation & Amortization | $302K-31.2% | $332K-24.9% | $378K-13.9% | $427K-2.7% | $439K+0.9% | $442K+2.3% | $439K+12.6% | $439K+1.6% |
| Stock-Based Compensation | $172K+60.7% | $172K-94.8% | N/A | $24K-93.4% | $107K-71.8% | $3.3M+773.8% | N/A | $365K-61.8% |
| Capital Expenditures | $0-100.0% | $0-100.0% | $34K-59.5% | $110K-67.5% | $51K-91.9% | $94K-63.1% | $84K-27.0% | $338K+924.2% |
| Free Cash Flow | -$4.5M+25.2% | -$9.0M-31.6% | -$23.0M-247.0% | -$4.4M+29.3% | -$6.0M+49.7% | -$6.8M+8.6% | -$6.6M-86.7% | -$6.2M-306.8% |
| Investing Cash Flow | -$4K+92.2% | $9K+109.6% | -$34K+59.5% | -$110K+67.5% | -$51K+91.9% | -$94K+63.1% | -$84K+27.0% | -$338K-100.5% |
| Financing Cash Flow | $0 | $0+100.0% | $0-100.0% | $0-100.0% | $0-100.0% | -$10.3M-201.9% | $283K | $64K+1180.0% |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
XBIT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -5.2%-4.2pp | -4.1%+2.1pp | N/A | -3.6%-1.0pp | -1.0%+5.6pp | -6.2%-1.4pp | N/A | -2.6%+0.7pp |
| Return on Assets | -5.0%-4.0pp | -3.9%+2.0pp | N/A | -3.5%-1.1pp | -1.0%+5.1pp | -6.0%-1.6pp | N/A | -2.4%+0.8pp |
| Current Ratio | 33.15-7.0x | 39.03+9.9x | 16.01+4.5x | 41.78+30.2x | 40.16+29.0x | 29.15+17.1x | 11.56-21.5x | 11.57-27.0x |
| Debt-to-Equity | 0.040.0x | 0.040.0x | 0.070.0x | 0.03-0.1x | 0.03-0.1x | 0.040.0x | 0.09+0.1x | 0.09+0.1x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| XBiotech Inc XBIT | FY2025 | N/A | -$45.5M | N/A | $69.8M | — |
| InflaRx N.V. IFRX | FY2025 | $20K | N/A | N/A | $235.8M | — |
| Ovid Therapeutics Inc. OVID | FY2025 | $7.3M | -$17.4M | N/A | $480.4M | 66/100 |
| VAXART INC VXRT | FY2025 | $237.3M | $16K | 0.0% | $103.2M | — |
| CervoMed Inc. CRVO | FY2025 | $4.0M | -$27.0M | N/A | $48.7M | 45/100 |
| Quince Therapeutics, Inc. QNCX | FY2025 | N/A | -$84.0M | N/A | $32.3M | — |
Where XBiotech Inc Ranks
Frequently Asked Questions
Is XBiotech Inc profitable?
No, XBiotech Inc (XBIT) reported a net income of -$45.5M in fiscal year 2025.
What is XBiotech Inc's EBITDA?
XBiotech Inc (XBIT) had EBITDA of -$54.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is XBiotech Inc's return on equity (ROE)?
XBiotech Inc (XBIT) has a return on equity of -32.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is XBiotech Inc's free cash flow?
XBiotech Inc (XBIT) recorded an outflow of $40.2M in free cash flow during fiscal year 2025. This represents a -24.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is XBiotech Inc's operating cash flow?
XBiotech Inc (XBIT) recorded an outflow of $39.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are XBiotech Inc's total assets?
XBiotech Inc (XBIT) had $150.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are XBiotech Inc's capital expenditures?
XBiotech Inc (XBIT) invested $289K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does XBiotech Inc spend on research and development?
XBiotech Inc (XBIT) invested $47.4M in research and development during fiscal year 2025.
What is XBiotech Inc's current ratio?
XBiotech Inc (XBIT) had a current ratio of 16.01 as of fiscal year 2025, which is generally considered healthy.
What is XBiotech Inc's debt-to-equity ratio?
XBiotech Inc (XBIT) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is XBiotech Inc's return on assets (ROA)?
XBiotech Inc (XBIT) had a return on assets of -30.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is XBiotech Inc's P/E ratio?
XBiotech Inc (XBIT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $69.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is XBiotech Inc's price-to-sales ratio?
XBiotech Inc (XBIT) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $69.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does XBiotech Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, XBiotech Inc (XBIT) held $125.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $39.9M over that year. Dividing the one by the other, the reported balance equals about 38 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is XBiotech Inc's Piotroski F-Score?
XBiotech Inc (XBIT) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are XBiotech Inc's earnings high quality?
XBiotech Inc (XBIT) reported a net loss of $45.5M while operations used $39.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can XBiotech Inc cover its interest payments?
XBiotech Inc (XBIT) reported an operating loss of $55.7M against $88K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.